308 related articles for article (PubMed ID: 36478475)
1. Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors.
Gupta AK; Wang T; Polla Ravi S; Bamimore MA; Piguet V; Tosti A
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):666-679. PubMed ID: 36478475
[TBL] [Abstract][Full Text] [Related]
2. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
Eisman S; Sinclair R
Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
[TBL] [Abstract][Full Text] [Related]
3. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B; Guttman-Yassky E; Peeva E; Banerjee A; Sinclair R; Pavel AB; Zhu L; Cox LA; Craiglow B; Chen L; Banfield C; Page K; Zhang W; Vincent MS
J Am Acad Dermatol; 2021 Aug; 85(2):379-387. PubMed ID: 33757798
[TBL] [Abstract][Full Text] [Related]
4. Janus kinase inhibitors for alopecia areata.
King BA; Craiglow BG
J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
[TBL] [Abstract][Full Text] [Related]
5. Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review.
Egeberg A; Linsell L; Johansson E; Durand F; Yu G; Vañó-Galván S
Dermatol Ther (Heidelb); 2023 Dec; 13(12):2951-2991. PubMed ID: 37833617
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta-analysis.
Husein-ElAhmed H; Husein-ElAhmed S
J Eur Acad Dermatol Venereol; 2024 May; 38(5):835-843. PubMed ID: 38279559
[TBL] [Abstract][Full Text] [Related]
7. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
Guttman-Yassky E; Pavel AB; Diaz A; Zhang N; Del Duca E; Estrada Y; King B; Banerjee A; Banfield C; Cox LA; Dowty ME; Page K; Vincent MS; Zhang W; Zhu L; Peeva E
J Allergy Clin Immunol; 2022 Apr; 149(4):1318-1328. PubMed ID: 34863853
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase inhibitors for alopecia areata: A narrative review.
Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
[TBL] [Abstract][Full Text] [Related]
10. Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.
Papierzewska M; Waśkiel-Burnat A; Rudnicka L
Clin Drug Investig; 2023 May; 43(5):325-334. PubMed ID: 37138134
[TBL] [Abstract][Full Text] [Related]
11. The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta-analyses of clinical trials.
Gupta AK; Wang T; Bamimore MA; Piguet V; Tosti A
J Cosmet Dermatol; 2023 Sep; 22(9):2553-2559. PubMed ID: 37452455
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.
Ramírez-Marín HA; Tosti A
Drug Des Devel Ther; 2022; 16():363-374. PubMed ID: 35210753
[TBL] [Abstract][Full Text] [Related]
13. [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
Ramot Y; Zlotogorski A
Harefuah; 2020 Jan; 159(1):38-42. PubMed ID: 31930807
[TBL] [Abstract][Full Text] [Related]
14. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
[TBL] [Abstract][Full Text] [Related]
15. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
16. Alopecia areata: What's new in the diagnosis and treatment with JAK inhibitors?
Dainichi T; Iwata M; Kaku Y
J Dermatol; 2024 Feb; 51(2):196-209. PubMed ID: 38087654
[TBL] [Abstract][Full Text] [Related]
17. Overview of alopecia areata for managed care and payer stakeholders in the United States.
King B; Pezalla E; Fung S; Tran H; Bourret JA; Peeples-Lamirande K; Takiya L; Napatalung L
J Manag Care Spec Pharm; 2023 Jul; 29(7):848-856. PubMed ID: 37219075
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for the treatment of alopecia areata.
Ramírez-Marín HA; Tosti A
Expert Opin Emerg Drugs; 2022 Dec; 27(4):379-387. PubMed ID: 36408593
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis.
Barati Sedeh F; Michaelsdóttir TE; Henning MAS; Jemec GBE; Ibler KS
Acta Derm Venereol; 2023 Jan; 103():adv00855. PubMed ID: 36695751
[TBL] [Abstract][Full Text] [Related]
20. Novel investigational drugs for alopecia areata and future perspectives.
Chim I; Ghiya R; Sinclair RD; Eisman S
Expert Opin Investig Drugs; 2024 May; ():1-9. PubMed ID: 38682280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]